WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device

Boston Scientific’s GuidePoint Reimbursement Resources are designed to specifically assist physician and hospital providers to navigate through the coding, coverage, and payment environment for new and innovative technologies such as the WATCHMAN LAAC Device.

On February 8, 2016, the Centers for Medicare and Medicaid Services (CMS) issued a final decision memo supporting the national coverage determination (NCD) for percutaneous LAAC therapy when specific conditions are met.  This major milestone provides appropriate and uniform coverage for Medicare beneficiaries that for the most part are consistent with the WATCHMAN FDA label.  Our GuidePoint Reimbursement Resources have been updated to reflect the positive NCD to assist physicians and hospitals in seeking coverage and payment consideration of WATCHMAN implants on a case-by-case basis from private payers and provide additional information on the NCD.

See More